Merck acquires Grzybowski Scientific Inventions to expand chemical synthesis offering

MerckMerck, a leading science and technology company, today announced the acquisition of Grzybowski Scientific Inventions (GSI), a company that developed the revolutionary computer-aided retro-synthesis tool, Chematica. Chematica uses advanced reaction rules and proprietary algorithms to identify synthesis pathways that meet user-defined constraints. Financial details of the transaction were not disclosed.

"With a 350-year legacy in the pharmaceutical and chemistry business, we recognize the attractiveness of the chemical synthesis and cheminformatics market and how it complements our existing leadership position in chemicals and reagents," said Udit Batra, Member of the Merck Executive Board and CEO, Life Science.

Virtual synthesis significantly reduces the time between chemical target conception and route evaluation by using a lab's preferences to filter millions of data points. The tool quickly and efficiently provides optimized routes, providing significant benefit to all researchers, especially those working in medicinal chemistry and drug discovery.

GSI's knowledge base of tens of thousands of expert-defined rules of chemical reactivity, combined with proprietary algorithms, enables the program to scrutinize millions of synthetic pathways and to choose the routes that lead to desired targets in the most cost-effective way.

"As chemists who grew up with Sigma-Aldrich and Millipore in the lab, we couldn’t be more proud to be acquired by a company with such a long legacy and sincere interest in chemistry," said Bartosz Grzybowski, founder of GSI and inventor of Chematica. "Combining our revolutionary planning tool with Merck’s large number of available starting materials, and its industry leading e-commerce platform, will provide immense value to our customers."

The Chematica tool is available now through a limited release for users in academia and in industry.

About Grzybowski Scientific Inventions (GSI)
Grzybowski Scientific Inventions (GSI) is a start-up company with exclusive licensing, development, marketing and sales rights to the revolutionary chemistry decision-making and synthetic planning software product Chematica. Since its establishment in December 2013, GSI has successfully engaged a clientele composed of a wide range of industries as well as academic and government institutions from all over the world. Today, Chematica is widely recognized as the first computer program capable of "chemical thinking" and the only expert system able to design chemically viable synthetic pathways for complex targets - including drugs, natural products as well as theoretical molecules - within seconds.

About Merck
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life - from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions. In 2016, Merck generated sales of € 15.0 billion in 66 countries.

Founded in 1668, Merck is the world's oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, MilliporeSigma and EMD Performance Materials.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]